The Phase III trial of clostridial collagenase for residual stage Dupuytren's disease aims to establish the drug's safety and efficacy compared to placebo. Given the estimated enrollment of 72 patients and the completion date in April 2004, the results could provide critical data for market entry. Dupuytren's disease affects a significant patient population, and effective treatments are limited, suggesting a potential market opportunity. The competitive landscape includes surgical interventions and other non-surgical treatments, but if proven effective, clostridial collagenase could position itself as a preferred non-invasive option. Diligence should focus on the regulatory pathway, potential reimbursement scenarios, and the need for post-marketing studies to confirm long-term efficacy and safety.